Title

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Document Type

Article

Publication Date

11-14-2017

Keywords

Animals; Cells, Cultured; Heterografts; Humans; Melanoma; Mice; Xenograft Model Antitumor Assays; BRAF inhibitor resistance; ERK inhibitor; MDM2 inhibitor; PI3K beta inhibitor; immune checkpoint blockade; in vivo models; melanoma; melanoma brain metastasis; patient-derived xenografts; targeted therapy

Abstract

Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups.

Clinical Institute

Cancer

Department

Oncology

Department

Dermatology

Share

COinS